The changes mark the second major revision to the 2022 antibody-drug conjugate-focused alliance between the US and Chinese firms, which is now focusing on ADCs against Trop2, Nectin-4 and other undisclosed targets. Meanwhile, the results from other trials with Claudin 18.2 ADCs have used varying definitions of high expression, with differing results.
Merck brings onboard a bispecific antibody-drug conjugate while ditching a Claudin 18.2-targeting ADC from Kelun-Biotech. • Source: Shutterstock
Merck & Co., Inc. has tweaked for the second time the lineup of antibody-drug conjugates (ADCs) it in-licensed from Chinese partner Kelun-Biotech in 2022, removing a Claudin 18.2-targeting ADC but exercising an option to add a adding a bispecific.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
